SCM
ORIC icon

Silverarc Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Silverarc Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.39M Buy
+682,600
New +$6.19M 0.77% 41

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Silverarc Capital Management's ORIC Position: Q2 2026 in Review

Silverarc Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 33% in Q2 2026, selling an estimated $3.27M and leaving 738,873 shares worth $8M. The position accounts for 0.83% of the portfolio, ranked #40.

Silverarc Capital Management first reported a position in ORIC in Q2 2022 and has held it in 17 quarters since. The position peaked at $23.4M in Q3 2025. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Silverarc Capital Management held 738,873 shares of Oric Pharmaceuticals worth $8M as of Q2 2026.
  • Silverarc Capital Management sold 361,137 Oric Pharmaceuticals shares in Q2 2026, an estimated $3.27M.
  • Oric Pharmaceuticals made up 0.83% of Silverarc Capital Management's portfolio in Q2 2026, its #40 holding.
  • Silverarc Capital Management first reported a position in Oric Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Silverarc Capital Management's Oric Pharmaceuticals position peaked at $23.4M in Q3 2025.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.